139 related articles for article (PubMed ID: 21173788)
1. Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia.
Liu W; Downing AC; Munsie LM; Chen P; Reed MR; Ruble CL; Landschulz KT; Kinon BJ; Nisenbaum LK
Pharmacogenomics J; 2012 Jun; 12(3):246-54. PubMed ID: 21173788
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Kinon BJ; Zhang L; Millen BA; Osuntokun OO; Williams JE; Kollack-Walker S; Jackson K; Kryzhanovskaya L; Jarkova N;
J Clin Psychopharmacol; 2011 Jun; 31(3):349-55. PubMed ID: 21508856
[TBL] [Abstract][Full Text] [Related]
3. Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia.
Kinon BJ; Gómez JC
Neuropharmacology; 2013 Mar; 66():82-6. PubMed ID: 22722029
[TBL] [Abstract][Full Text] [Related]
4. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
Stauffer VL; Millen BA; Andersen S; Kinon BJ; Lagrandeur L; Lindenmayer JP; Gomez JC
Schizophr Res; 2013 Nov; 150(2-3):434-41. PubMed ID: 24035403
[TBL] [Abstract][Full Text] [Related]
5. A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia.
Downing AM; Kinon BJ; Millen BA; Zhang L; Liu L; Morozova MA; Brenner R; Rayle TJ; Nisenbaum L; Zhao F; Gomez JC
BMC Psychiatry; 2014 Dec; 14():351. PubMed ID: 25539791
[TBL] [Abstract][Full Text] [Related]
6. When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy.
Marek GJ
Curr Pharm Des; 2015; 21(26):3788-96. PubMed ID: 26044978
[TBL] [Abstract][Full Text] [Related]
7. [The use of mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial].
Mosolov SN; Smulevich AB; Neznanov NG; Tochilov VA; Andreev BV; Avedisova AS; Bardenshteĭn LM; Gurovich IIa; Reznik AM; Zharkova NB; Martenyi F
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(7):16-23. PubMed ID: 20639852
[TBL] [Abstract][Full Text] [Related]
8. Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia.
Mössner R; Schuhmacher A; Schulze-Rauschenbach S; Kühn KU; Rujescu D; Rietschel M; Zobel A; Franke P; Wölwer W; Gaebel W; Häfner H; Wagner M; Maier W
Eur Neuropsychopharmacol; 2008 Oct; 18(10):768-72. PubMed ID: 18614340
[TBL] [Abstract][Full Text] [Related]
9. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
Fell MJ; McKinzie DL; Monn JA; Svensson KA
Neuropharmacology; 2012 Mar; 62(3):1473-83. PubMed ID: 21704048
[TBL] [Abstract][Full Text] [Related]
10. [Targeting metabotropic glutamate receptors to develop novel antipsychotics].
Chaki S; Yoshida S; Okuyama S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):207-13. PubMed ID: 21226317
[TBL] [Abstract][Full Text] [Related]
11. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Patil ST; Zhang L; Martenyi F; Lowe SL; Jackson KA; Andreev BV; Avedisova AS; Bardenstein LM; Gurovich IY; Morozova MA; Mosolov SN; Neznanov NG; Reznik AM; Smulevich AB; Tochilov VA; Johnson BG; Monn JA; Schoepp DD
Nat Med; 2007 Sep; 13(9):1102-7. PubMed ID: 17767166
[TBL] [Abstract][Full Text] [Related]
12. The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.
Sacchetti E; Magri C; Minelli A; Valsecchi P; Traversa M; Calza S; Vita A; Gennarelli M
Pharmacogenomics J; 2017 Mar; 17(2):146-154. PubMed ID: 26856250
[TBL] [Abstract][Full Text] [Related]
13. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment.
Bishop JR; Ellingrod VL; Moline J; Miller D
Schizophr Res; 2005 Sep; 77(2-3):253-60. PubMed ID: 15913960
[TBL] [Abstract][Full Text] [Related]
14. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.
Gunes A; Melkersson KI; Scordo MG; Dahl ML
J Clin Psychopharmacol; 2009 Feb; 29(1):65-8. PubMed ID: 19142110
[TBL] [Abstract][Full Text] [Related]
15. Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia?
Hopkins CR
ACS Chem Neurosci; 2013 Feb; 4(2):211-3. PubMed ID: 23421671
[TBL] [Abstract][Full Text] [Related]
16. Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs.
Peñas-Lledó EM; Dorado P; Cáceres MC; de la Rubia A; Llerena A
Clin Chem Lab Med; 2007; 45(7):835-8. PubMed ID: 17617023
[TBL] [Abstract][Full Text] [Related]
17. Comment on "A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia" by Kinon et al.
Seeman P
J Clin Psychopharmacol; 2012 Apr; 32(2):291-2; author reply 292-293. PubMed ID: 22388160
[No Abstract] [Full Text] [Related]
18. Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies.
Ayan-Oshodi M; Wondmagegnehu ET; Lowe SL; Kryzhanovskaya L; Walker DJ; Kinon BJ
J Clin Psychopharmacol; 2012 Jun; 32(3):408-11. PubMed ID: 22544017
[TBL] [Abstract][Full Text] [Related]
19. Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patients.
Melkersson KI; Gunes A; Dahl ML
Hum Psychopharmacol; 2010; 25(4):347-52. PubMed ID: 20521326
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
Fell MJ; Svensson KA; Johnson BG; Schoepp DD
J Pharmacol Exp Ther; 2008 Jul; 326(1):209-17. PubMed ID: 18424625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
